Clinical Pathology Associates, Austin, TX, USA.
Pathology Research Core, Mayo Clinic, Rochester, MN, USA.
Virchows Arch. 2021 Feb;478(2):201-207. doi: 10.1007/s00428-020-02868-8. Epub 2020 Jun 25.
This study aims to investigate the utility of digital protocols for Ki-67 immunohistochemistry quantitative analysis ("hot spot" method) in the setting of well-differentiated hepatocellular neoplasms. Resection cases of typical hepatic adenomas (HAs) (n = 40), atypical HAs (n = 9), and well-differentiated hepatocellular carcinomas (WD HCCs) (n = 56) were selected. HAs were further classified by immunohistochemistry using antibodies against liver fatty acid binding protein, glutamine synthetase, B-catenin, hepatic serum amyloid A, and C-reactive protein. Ki-67 proliferative index by immunohistochemistry was evaluated in all cases by digital analysis using a modified neuroendocrine tumor "hot spot" protocol. The proliferative rate of HAs (typical, median 1.2% (range 0-7.4%) and atypical, median 1.0% (range 0.3-3%)) was significantly lower than that of WD HCCs (median 4.5%, range 0-49.8%) (P < 0.0001). Only a few (7.5%) of the adenomas (all inflammatory/telangiectatic type) had proliferative rates higher than 4%, compared to most (51%) of HCCs. Ki-67 is a potentially useful adjunct marker in the evaluation of WD hepatocellular neoplasms, as "hot spot" proliferative rates are consistently very low in HAs but vary significantly in WD HCCs.
本研究旨在探讨 Ki-67 免疫组化定量分析(“热点”法)在分化良好的肝细胞肿瘤中的应用价值。选择了典型肝细胞腺瘤(HA)(n=40)、非典型 HA(n=9)和分化良好的肝细胞癌(WD HCC)(n=56)的切除病例。通过针对肝脂肪酸结合蛋白、谷氨酰胺合成酶、β-连环蛋白、肝血清淀粉样蛋白 A 和 C 反应蛋白的免疫组化进一步对 HA 进行分类。使用改良的神经内分泌肿瘤“热点”方案通过数字分析评估所有病例的 Ki-67 免疫组化增殖指数。HA 的增殖率(典型,中位数 1.2%(范围 0-7.4%)和非典型,中位数 1.0%(范围 0.3-3%))明显低于 WD HCC(中位数 4.5%,范围 0-49.8%)(P<0.0001)。只有少数(7.5%)腺瘤(均为炎症/静脉扩张型)的增殖率高于 4%,而大多数(51%)HCC 则如此。Ki-67 是评估 WD 肝细胞肿瘤的潜在有用辅助标志物,因为“热点”增殖率在 HA 中始终非常低,但在 WD HCC 中差异显著。